Hot Safest Stocks To Watch For 2018


Shutterstock

In my last article, I pointed out that the S&P 500 is far from overpriced right now. All you have to do is dig a bit deeper than first-level investors to see that this is true.

And while I do think it’s a good idea to buy stocks right now, I don’t think the SPDR S&P 500 ETF (SPY) or Vanguard 500 ETF (VOO) are good ways to do it.

Before I get into why, let me first explain what these funds are.

VOO and SPY are passive index funds whose job is to track the market, not beat it. So if you buy them and the market goes up, you’re fine. And if you have a long time horizon—meaning you’re investing money you don’t expect to touch for 30 years or more—you’ll also probably do alright with these funds.


But all right isn’t good enough.

Hot Safest Stocks To Watch For 2018: Realogy Holdings Corp.(RLGY)

Advisors’ Opinion:

  • [By Monica Wolfe]

    Realogy Holdings (RLGY)

    Paulsons third largest holding goes to Realogy Holdings. The guru holds on to 12,957,700 shares, representing 4.4% of his total portfolio and 8.87% of the companys shares outstanding.

  • [By Lisa Abramowicz]

    Drugstore chain Rite Aid Corp. (RAD) and residential property firm Realogy Corp. (RLGY) are two of the 283 junk-rated borrowers identified in March 2009 by Moodys Investors Service as being at the highest risk of default that have since sold bonds.

  • [By Chad Tracy]

    Investments in Claire's retail stores, Realogy Holdings (NYSE: RLGY), and Harrah's Entertainment all came under pressure as the global credit crisis hit. Apollo was forced to shut off cash interest payments to investors and to issue more debt.  

Hot Safest Stocks To Watch For 2018: New York REIT, Inc.(NYRT)


Advisors’ Opinion:

  • [By Paul Ausick]

    New York REIT Inc. (NYSE: NYRT) dropped about 11.8% Thursday to post a new 52-week low of $8.55 after closing at $9.69 on Wednesday. The stock’s 52-week high is $10.15. Volume was nearly 20 times the daily average of around 1.9 million shares. The company, which is in the process of liquidating its assets in New York City, announced quarterly results Wednesday afternoon, including a liquidation value of the portfolio of $9.25 per share.

Hot Safest Stocks To Watch For 2018: Liberty Interactive Corporation(QVCA)


Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    QVC (QVCA) was upgraded to buy from neutral at Bank of America/Merrill Lynch. $25 price target. The company can turn its sales around and deserves a higher multiple, analysts said. 

Hot Safest Stocks To Watch For 2018: Biotricity (BTCY)

Advisors’ Opinion:

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.


    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.


    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.


    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.


    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

  • [By James E. Brumley]

    Biotricity Inc (OTCMKTS:BTCY), a developer of remote health-monitoring devices, reminded us not so gently today that while it’s waiting on the last of the necessary approvals from the FDA for its hardware, it’s still moving the ball downfield (so to speak). That is to say, it’s already lined up a manufacturer for its so-called Bioflux cardiac monitor for when the last green light is given, and it’s a good one…. Providence Enterprise . That’s the same company that makes some of the equipment and goods within your sight right now.


    Biotricity is the name behind two pieces of technology, both of which are nearing the end of their development. One is the aforementioned Bioflux, and the other is called biolife…. the latter for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market this year. In fact, the company demonstrated its IoT-connected bioflux at this year’s Mobile World Congress (MWC) 2017 in Barcelona, Spain a couple of weeks ago. The crowd liked what it saw.

    The marketable version of the device isn’t available yet; it’s still going through the approval process. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device, and that portion of the review takes longer.


    Still, the company is rightfully optimistic, so much so that it’s already lined up a company to manufacture the Bioflux device once the final approval and final specs are in. That company is Providence Enterprise, which has a long history in making drug delivery and diagnostic equipment, as well as plenty of experience making electronics. The Bioflux will be a blend of both capabilities.

    It’s in

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.


    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.


    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Matthew Briar]

    In October, medical technology developer Biotricity Inc. (OTCMKTS:BTCY) announced part of its heart-monitoring hardware received the necessary 501k clearance from the Food & Drug Administration. It was a not-so-subtle reminder that the company is nearing the end of the R&D journey with its bioflux device, which provides caregivers round-the-clock monitoring of a heart patient’s vital stats. BTCY could have the device on the market within a matter of weeks, putting the organization into a multi-billion dollar market with a platform like no other.

    And yet, heart-monitoring is only going to be a part of what the company does.

    Another news later that same month was a not-so-subtle reminder…. Biotricity Inc. is already eyeing the entry into other markets aside from the cardiac market that would benefit from remote monitoring.

    One has to back-track to the September 29th press release to set the stage. That’s when the company announced it would take the same basic remote-monitoring technology and apply it to fetal monitoring and sleep apnea, at least. The way the PR read left open the possibility to even more medically-related uses.

    For some it may have been a read-it-and-forget-it affair. Lots of companies announce their intentions, and then get around to doing it whenever they feel like it, IF they feel like it. Biotricity wasn’t just blowing smoke though. In October the company announced that its primary development partner — the University of Calgary — and it laid out specific plans to create ‘remote monitoring mobile devices in a number of clinical settings, including peri-operative medicine, maternal/fetal medicine and acute and chronic care medicine in order to facilitate the application of “smart” medical grade wearables to the hospital and out-patient settings.’

    This second mention of the idea suggests it’s going to happen sooner than later, even as the company continues to push bioflux to

Leave a Reply

Your email address will not be published. Required fields are marked *